SAN DIEGO, April 27 /PRNewswire-FirstCall/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD) announced today the pricing of its public offering of 4,947,229shares of its common stock. The public offering price of $12.00 per shareresulted in gross proceeds of $59.4 million and net proceeds, afterunderwriting commissions and other offering expenses, of $55.6 million toACADIA. ACADIA also granted the underwriters a 30-day option to purchase upto 742,084 additional shares of its common stock, which could raise the netproceeds to ACADIA to $64.0 million, if exercised in full. All of the sharesare being sold by ACADIA.
The book-running managers for the offering are Banc of America SecuritiesLLC and Lehman Brothers Inc. and the co-managers are Piper Jaffray & Co., JMPSecurities LLC and Canaccord Adams Inc.
A registration statement relating to these securities was filed and hasbeen declared effective by the Securities and Exchange Commission. This pressrelease shall not constitute an offer to sell or the solicitation of an offerto buy these securities, nor shall there be any sale of these securities, inany jurisdiction in which such offer, solicitation or sale would be unlawfulprior to registration or qualification under the securities laws of any suchjurisdiction. The offering and sale of these securities may be made only bymeans of the final prospectus supplement and related prospectus relating tothe offering, copies of which may be obtained, when available, by contactingBanc of America Securities LLC, Capital Markets (Prospectus Fulfillment) bye-mail to dg.prospectus_distribution@bofasecurities.com or by mail to Banc ofAmerica Securities LLC, Capital Markets Operations, 100 West 33rd Street,3rd Floor, New York, NY 10001 and Lehman Brothers Inc. by email tomonica_castillo@adp.com or by fax to (631) 254-7268 or by mail to LehmanBrothers, c/o ADP Financial Services, Prospectus Fulfillment, 1155 Long IslandAvenue, Edgewood, NY 11717.
ACADIA Pharmaceuticals is a biopharmaceutical company with its corporateheadquarters located in San Diego, California and research and developmentoperations in both San Diego and Malmo, Sweden.
Contacts:
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Chief Financial Officer
(858) 558-2871